Blanket Purchase Agreement V797D50602-36E79721A0016
Award Date
6/1/21
Last Date to Order
9/14/21
Federal Agency
National Acquisition Center
Awardee
Travere Therapeutics, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
Travere Therapeutics, Inc. holds a Blanket Purchase Agreement (BPA) with the Department of Veterans Affairs (VA) National Acquisition Center valued at $25,000,000. This BPA is specifically for the procurement of Travere's pharmaceutical products Thiola and Cholbam, which are used to treat rare kidney and liver conditions, respectively. Travere also holds a Federal Supply Schedule (FSS) contract with the VA for Pharmaceuticals and Drugs (FSS-61-IB), valued up to $14,970,593.10, which serves as...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Ucb, Inc. for the procurement of pharmaceutical products. Specifically, the BPA covers Cimzia, Nayzilam, Neupro, Vimpat, Briviact, and Keppra for a potential value of $609,090,892.65. The contract was awarded on October 20, 2022 and has a performance period through the last date to order of November 14, 2022. No set-aside provisions were applied to this single-award BPA. The BPA was...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to UCB, Inc., a global biopharmaceutical company, under the General Services Administration's Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs. The single-award BPA, valued at $264,295.45, covers the procurement of the drug ZilbrysQ to treat patients within the VA healthcare system. Additionally, UCB, Inc. holds a larger BPA valued at $609,090,892.65 that...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to United Therapeutics Corporation, a self-certified small disadvantaged business and for-profit manufacturer of pharmaceutical goods. The BPA has a ceiling value of $207,127,385 and a performance period extending through April 2026. It allows the VA to procure specialized pharmaceutical products from United Therapeutics' portfolio, including Orenitram, Remodulin, Tyvaso,...
Travere Therapeutics, Inc., a biopharmaceutical company specializing in rare disease therapies, holds a $14,970,593.10 Federal Supply Schedule (FSS) contract with the U.S. Department of Veterans Affairs (VA) under the Pharmaceuticals and Drugs (FSS-61-IB) schedule. This allows the VA to issue delivery orders for Travere's full range of pharmaceutical products, including Thiola (tiopronin) for cystinuria, Cholbam (cholic acid) for bile acid synthesis disorders, Chenodal (chenodiol) for...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Akebia Therapeutics, Inc. as a single-award contract under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The BPA has a ceiling value of $10,254,764.65 and a period of performance from April 25, 2025 to April 24, 2026. The purpose of this BPA is to provide the VA with the pharmaceutical products VAFSEO and AURYXIA. No set-asides were used for this award....
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer, to provide critical medications for the treatment of rare diseases such as pulmonary arterial hypertension. The $118.5 million BPA covers the period from August 2024 to August 2025 and allows the VA, Federal Bureau of Prisons, and other federal agencies to procure specialized drug therapies like...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency of the U.S. government, to Vanda Pharmaceuticals Inc. (Vanda) on October 26, 2022. The single-award BPA has a ceiling value of $3,069,780 and a period of performance through August 31, 2024. The BPA is for the procurement of Hetlioz (tasimelteon), a medication used to treat Non-24-Hour Sleep-Wake Disorder in blind adults and patients with Smith-Magenis Syndrome. Vanda is the manufacturer of...
This Blanket Purchase Agreement (BPA) is a single-award indefinite delivery vehicle (IDV) contract awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Intercept Pharmaceuticals Inc. (Intercept). The BPA, with a ceiling value of $21,000,000, provides an efficient means for the VA to procure Intercept's drug Ocaliva for the treatment of primary biliary cholangitis in veterans who have an inadequate response to ursodeoxycholic acid alone. The BPA falls under the...
The Blanket Purchase Agreement (BPA) is a federal contract indefinite delivery vehicle (IDV) awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), to Genzyme Corporation, doing business as Sanofi Genzyme. The BPA has a ceiling value of $3,000,000 and a period of performance from June 6, 2024 to June 5, 2026. The purpose of the BPA is to provide the VA with a streamlined contracting method to procure specialty pharmaceutical products,...